Table 2.

Ongoing clinical trials for evaluation of Remdesivir (https://clinicaltrials.gov/ct2/results).

Clinical Trial Number	Study Description	Phase	Dose	Location
NCT04280705	Adaptive COVID-19 Treatment Clinical Trial	3	200 mg i.v. on the first day, 100 mg once a day up to 10 days	United States
NCT04321616	Evaluating the Efficacy of various Anti-viral Drugs against COVID 19	2,3	100 mg i.v. daily up to 10 days; loading dose 200 mg at inclusion will be given.	Norway
NCT04315948	Trial of Treatments against COVID-19 in Adult Hospitalized patients	3	100 mg i.v. loading dose on the first day, 100 mg once-daily I.v. maintenance dose up to 10 days	France
NCT04292899	Clinical Trial Study for Evaluation of the Safety and Activity of Remdesivir in Patients With Severe Coronavirus Disease	3	PartA: (Patients that are not mechanically ventilated) 200 mg given on the first day followed by 100 mg on Days 2–5 PartA: (Patients Not Mechanically Ventilated) 200 mg on the first day and then 100 mg on Days 2–10. PartB: (Extension) 200 mg on the first day then 100 mg on Days 2–10. Part B: (Patients provided with Mechanical Ventilation) 200 mg on the first day followed 100 mg on Days 2–10	United States
NCT04292730	Clinical Trial for Evaluation of the Safety and Activity of Remdesivir in Patients	3	PartA: (Patients not mechanically ventilated) 200 mg on the first day followed by 100 mg on Days 2–5 PartA: (Patients Not Mechanically Ventilated) 200 mg on the first day followed by 100 mg on Days 2–10. PartB: (Extension) 200 mg on the first day followed by 100 mg on Days 2–10. Part B: (Patients provided with Mechanical Ventilation) 200 mg on the first day followed by 100 mg on Days 2–10	United States